On January 10, 2022 Vyant Bio, Inc. ("Vyant Bio", "Company") (Nasdaq: VYNT), an emerging global drug discovery company, reported that it is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) diseases (Press release, Vyant Bio, JAN 10, 2022, View Source [SID1234598518]). Today, Vyant Bio announced that it will be participating in the H.C. Wainwright Bioconnect Conference. The event is being held virtually from January 10-13, 2022. Registered attendees can access the recorded presentation on-demand (24×7) for the duration of the conference.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conference Date: January 10-13, 2022 (Monday-Thursday)
On-Demand Starts: 7:00 am ET – Monday, January 10, 2022
On-Demand Ends: 7:00 pm ET- Thursday, January, 13, 2022
Registration: View Source
During the presentation, Vyant Bio’s Chief Executive Officer, Jay Roberts, and Chief Scientific Officer, Robert Fremeau, Ph.D., will be discussing key highlights from 2021 and the scientific, business and strategic outlook for 2022. The presentation will be an archived recording will be made available in the Investors’ section of the Vyant Bio website.
If you are an institutional investor and would like to participate in this event please, click on the following link (View Source) to register for the H.C. Wainwright Bioconnect Conference. Once your registration is confirmed, you will be prompted to log into the conference website and will be able to request a one-on-one meeting with the Company.
Vyant Bio will also be available for virtual outside 1:1 meetings after the H.C. Wainwright Bioconnect Conference. Please contact Jennifer K. Zimmons, Ph.D. at [email protected] or +1 917.214.3514 for scheduling.